A Phase Ib Safety and Pharmacokinetics (PK)/ Pharmacodynamics (PD) Study to Determine the Dosage of Abraxane in Combination with Phenelzine Sulfate in Metastatic or Inoperable Locally Advanced Breast Cancer
Latest Information Update: 20 Jun 2022
At a glance
- Drugs Paclitaxel (Primary) ; Phenelzine (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Proof of concept
- Acronyms Epi-PRIMED
- Sponsors EpiAxis Therapeutics
- 08 Jun 2022 According to an EpiAxis Therapeutics media release, data published in cancer journal Frontiers of Oncology.
- 12 Nov 2019 Status changed from recruiting to completed.
- 01 Dec 2018 According to an EpiAxis Therapeutics media release, the company has expanded this study by including two additional recruitment centres. The two new centers are the Southern Medical Day Care Centre in Wollongong and at the Liverpool Cancer Therapy Centre. The principle investigators at these centre are Professor Phil Clingan and Dr Eugene Moylan, respectively.